Structure Therapeutics (GPCR) to Announce Quarterly Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, analysts expect Structure Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Structure Therapeutics Stock Up 2.6%

Shares of GPCR stock opened at $49.64 on Wednesday. The firm has a 50 day moving average of $46.89 and a 200-day moving average of $54.70. The company has a market cap of $3.53 billion, a price-to-earnings ratio of -57.06 and a beta of -1.43. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90.

Wall Street Analyst Weigh In

GPCR has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. HC Wainwright decreased their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. Finally, Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $110.55.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the company. HighTower Advisors LLC increased its stake in Structure Therapeutics by 3.6% during the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after purchasing an additional 320 shares in the last quarter. State of Wyoming lifted its stake in shares of Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after buying an additional 403 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Structure Therapeutics by 14.5% in the third quarter. Envestnet Asset Management Inc. now owns 12,220 shares of the company’s stock valued at $342,000 after buying an additional 1,544 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Structure Therapeutics in the fourth quarter valued at $127,000. Finally, State Street Corp grew its holdings in shares of Structure Therapeutics by 4.8% during the fourth quarter. State Street Corp now owns 48,224 shares of the company’s stock valued at $3,354,000 after buying an additional 2,207 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.